Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2005 - Concurrent cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy for p16-positive, locally advanced oropharyngeal cancer: A meta-analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Petar Suton

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

P. Suton1, M. Skelin2, I. Luksic3

Author affiliations

  • 1 Department Of Radiotherapy And Medical Oncology, University Hospital for Tumors, University Hospital Center Sisters of Mercy, 10000 - Zagreb/HR
  • 2 Pharmacy Department, OB General Hospital Sibenik, 22000 - Sibenik/HR
  • 3 Department Of Maxillofacial Surgery, University Hospital Dubrava, Zagreb/HR
More

Resources

Abstract 2005

Background

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. A special entity among HNSCCs is HPV-associated oropharyngeal cancer (OPC) with p16 positivity as a surrogate marker of cancer’s viral etiology. A standard of definitive treatment for these tumors is cisplatin (CDDP) given concurrently with radiotherapy (RT). Another possible option being investigated is replacement of CDDP with cetuximab (C225). However, the optimal treatment for HPV-positive OPC remains unclear, until ongoing studies provide more evidence on this matter. The aim of this meta-analysis is to provide guidance regarding treatment decision-making in this subgroup of patients.

Methods

We performed a systematic literature search using the MEDLINE, PubMed, EMBASE, Web of Science, ScienceDirect, and Scopus databases. Meta-analysis included studies which directly compared the efficacy of CDDP vs. C225 given concurrently with RT as definitive treatment of p16-positive and locally advanced/unresectable OPC. Primary endpoints included 2-year overall survival (OS) (death from any cause) and 2-year locoregional recurrence (LRR) (recurrence at primary site and/or regional lymph nodes), analysed separately. Six studies were included in the final analysis, including a total of 526 patients (range 18-205).

Results

2-year OS. There were 313 patients in the CDDP + RT group and 113 patients in the C225 + RT group. The pooled odds ratio (OR), calculated for CDDP + RT vs. C225 + RT, was 0.35 (95% CI, 0.17-0.71; P = 0.003). 2-year LRR. There were 382 patients in the CDDP + RT group and 144 patients in the C225 + RT group. The pooled OR, calculated for CDDP + RT vs. C225 + RT, was 0.25 (95% CI, 0.15-0.45; P < 0.0001).

Conclusions

According to our results, patients receiving CDDP with irradiation had 2.9 and 4-fold decreased risk for death from any cause and locoregional recurrence, respectively. Further investigations are needed in order to determine the optimal treatment modalities in both p16-positive and negative OPC. Until then, CDDP-based chemoradiotherapy should be considered as first line therapy option and standard of care in p16-positive and locally advanced/unresectable OPC.

Clinical trial identification

Legal entity responsible for the study

Petar Suton.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.